Key result
In isolated neonatal lamb hearts, administration of the ET-A receptor antagonist BE-18257B before reperfusion significantly improved recovery of LV function and coronary blood flow (P < .05).
Why the study?
Does an ET-A receptor antagonist or ET-1 alter postischemic recovery in isolated neonatal lamb hearts after hypothermic cardioplegic ischemia?
Population
22 isolated blood-perfused neonatal lamb hearts subjected to 2 hours of 10 degrees C cardioplegic ischemia
Comparison
Endothelin-A receptor antagonist BE-18257B or… vs Control hearts receiving no additional agent…
Design
Preclinical
Follow-up
30 minutes of reperfusion
Authors
Loading...
ET-1 may worsen postischemic recovery in neonatal hearts; leaves open whether ET-A antagonism improves clinical cardioplegia outcomes.
Does an ET-A receptor antagonist or ET-1 alter postischemic recovery in isolated neonatal lamb hearts after hypothermic cardioplegic ischemia?
p-value: p=< .05
Endothelin-A receptor antagonism improves postischemic recovery in neonatal lamb hearts, suggesting that unopposed ET-1 vasoconstriction contributes to ischemia/reperfusion injury.
Hiramatsu et al. (1995) studied Ischemia/reperfusion injury (n=22). Endothelin-A (ET-A) receptor antagonist BE-18257B or Endothelin-1 (ET-1) vs. Control was evaluated on Postischemic recovery of LV systolic and diastolic function, coronary blood flow, and myocardial oxygen consumption at 30 minutes of reperfusion (p=< .05). In isolated neonatal lamb hearts, administration of the ET-A receptor antagonist BE-18257B before reperfusion significantly improved recovery of LV function and coronary blood flow (P < .05).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: